ERBB2 and breast carcinoma: Stmn1 was overexpressed in breast cancer samples of 85.71% (6/7 samples) of triple negative, 87.50% (7/8 samples) of ER/PR+, HER2+, 77.78% (7/9 samples) ER/PR+, HER2− and 83.33% (5/6 samples) of ER/PR−, HER2+, when compared with that in adjacent normal breast tissues, respectively (Figure 9B).